Glucoryl M Forte 2 mg Tablet

• Type 2 diabetes mellitus

Glucoryl M Forte 2 mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:

• Headache
• Hypoglycemia (low blood glucose level)
• Nausea
• Diarrhea

Seek medical attention in case of any unusual or severe side effects immediately.

• Take Glucoryl M Forte 2 mg Tablet in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition.
• This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.
  
  

• Glucoryl M Forte 2 mg Tablet is an anti-diabetic medicine. It is a combination of Glimepiride (2mg) and Metformin (1000mg). As a sulfonylurea, glimepiride minimizes blood sugar by stimulating the pancreas to secrete more insulin.
• Metformin is a biguanide that increases the body's tolerance to insulin, reduces the liver's synthesis of glucose, and slows down the intestines' absorption of glucose.
  
  

• Suman, S. V. (2020). Efficacy and Safety of Voglibose Vs Glimepride in Combination with Metformin in Type 2 Diabetes: A randomized Controlled Trial (Doctoral dissertation).
• Sheikh, S., Nagendra, L., Sinha, B., Bansal, B., Dey, A., Kumar, S., ... & Prasad, A. (2024). Usage of glimepiride and metformin combination in type 2 diabetes patients with established complications in Indian settings. International Journal of Diabetes and Technology, 3(2), 74-79. https://journals.lww.com/ijdt/fulltext/2024/03020/usage_of_glimepiride_and_metformin_combination_in.6.aspx
• BANTWAL, G., AYYAR, V., KOVIL, R., CHAWLA, M., SHAH, T., KUMAR, S., ... & REVANKAR, S. (2021). Assessment of Clinical Experience of Triple Drug Fixed-dose Combination of Glimepiride, Metformin and Voglibose in the Management of Type 2 Diabetes Mellitus: A Retrospective Study. Journal of Clinical & Diagnostic Research, 15(9). https://www.researchgate.net/publication/357481699_Assessment_of_Clinical_Experience_of_Triple_Drug_Fixed-dose_Combination_of_Glimepiride_Metformin_and_Voglibose_in_the_Management_of_Type_2_Diabetes_Mellitus_A_Retrospective_Study
• Shin, K. H., Kim, S. E., Yoon, S. H., Cho, J. Y., Jang, I. J., Shin, S. G., & Yu, K. S. (2011). Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study. Clinical therapeutics, 33(11), 1809-1818. https://www.researchgate.net/publication/51755605_Pharmacokinetic_Comparison_of_a_New_Sustained-Release_Formulation_of_GlimepirideMetformin_1500_mg_Combination_Tablet_and_a_Sustained-Release_Formulation_of_GlimepirideMetformin_2500_mg_Combination_Tab
• Kim, B. H., Shin, K. H., Kim, J., Lim, K. S., Kim, K. P., Kim, J. R., ... & Yu, K. S. (2009). Pharmacokinetic comparison of a new glimepiride 1-mg+ metformin 500-mg combination tablet formulation and a glimepiride 2-mg+ metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. Clinical therapeutics, 31(11), 2755-2764.